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Abstract
Background: Astrogliosis is a common phenomenon after spinal cord injury (SCI). Although this process exerts
positive effects on axonal regeneration, excessive astrogliosis imparts negative effects on neuronal repair and
recovery. Epidermal growth factor receptor (EGFR) pathway is critical to the regulation of reactive astrogliosis, and
therefore is a potential target of therapeutics to better control the response. In this report, we aim to investigate
whether blocking EGFR signaling using an EGFR tyrosine kinase specific inhibitor can attenuate reactive astrogliosis
and promote functional recovery after a traumatic SCI.
Method: The astrocyte scratch injury model in vitro and the weight-drop SCI model in vivo were used as model
systems. PD168393 was used to inhibit EGFR signaling activation. Astrocytic activation and phosphorylated EGFR
(pEGFR) were observed after immunofluorescence staining and Western blot analysis. The rate of proliferation was
determined by immunofluorescence detection of BrdU-incorporating cells located next to the wound. The levels of
TNF-α, iNOS, COX-2 and IL-1β in the culture medium under different conditions were assayed by ELISA. Western
blot was performed to semi-quantify the expression of EGFR/pEGFR, glial fibrillary acid protein (GFAP) and
chondroitin sulfate proteoglycans (CSPGs). Myelin was stained by Luxol Fast Blue Staining. Cresyl violet eosin
staining was performed to analyze the lesion cavity volume and neuronal survival following injury. Finally, functional
scoring and residual urine recording were performed to show the rats’ recovery.
Results: EGFR phosphorylation was found to parallel astrocyte activation, and EGFR inhibitor PD168393 potently
inhibited scratch-induced reactive astrogliosis and proinflammatory cytokine/mediator secretion of reactive
astrocytes in vitro. Moreover, local administration of PD168393 in the injured area suppressed CSPGs production and
glial scar formation, and resulted in reduced demyelination and neuronal loss, which correlated with remarkable
hindlimb motor function and bladder improvement in SCI rats.
Conclusions: The specific EGFR inhibitor PD168393 can ameliorate excessive reactive astrogliosis and facilitate a
more favorable environment for axonal regeneration after SCI. As such, EGFR inhibitor may be a promising
therapeutic intervention in CNS injury.
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With few treatment options, spinal cord injury (SCI) can
result in irreversible neurologic deficits influenced by
axonal regeneration failure through and beyond the site
of injury. The pathogenesis of axonal regeneration failure
following SCI involves poor intrinsic central nervous sys-
tem (CNS) axon regeneration ability as well as the develop-
ment of an inhibitory growth environment that includes
glial scar formation around the injury site, and a major
group of inhibitory proteins in and around the scar known
as chondroitin sulfate proteoglycans (CSPGs) [1-3].
In response to SCI, astrocytes in the cord become
‘reactive’ and exhibit characteristics including hypertrophy,
upregulation of intermediate filament proteins such as glial
fibrillary acid protein (GFAP) and vimentin, and cell
proliferation [4]. The formation of the inhibitory glial
scar environment depends on such properties of reactive
astrocytes post-injury. As astrocyte proliferation could
r e s u l ti ni n c r e a s e ds c a rf o r m a t i o na n de l e v a t e dC S P G
production and deposition near the injury site, it is im-
portant to identify mechanisms regulating astrocyte react-
ive proliferation to potentially enhance axon regeneration
and recovery of function after SCI.
Known supportive factors for astrocyte proliferation in
CNS injury include growth factors and cytokines [5]. Spe-
cifically, epidermal growth factor (EGF) and transforming
growth factor-a (TGF-a) have been shown to play crucial
roles in the transformation of quiescent astrocytes toward a
reactive state [6]. Enhanced expression of the membrane-
localized target of these growth factors, the receptor tyro-
sine kinase epidermal growth factor receptor (EGFR), has
been observed in astrocytes following trauma to the CNS
[7,8]. Therefore, the EGFR pathway is commonly perceived
as a key signaling cascade by which to regulate and control
reactive astrogliosis and proliferation following SCI [8].
If so, inhibition of EGFR signaling may benefit axonal
regeneration and improve functional outcome in SCI.
PD168393 (4-[(3-bromophenyl) amino]-6-acrylami-
doquinazoline) is a potent, cell-permeable, specific and
irreversible inhibitor of EGFR [9,10], and acts by covalently
modifying cysteine-733, an amino acid located in the cata-
lytic domain of the adenosine triphosphate (ATP) binding
pocket [11]. Based on these properties, such a compound
would be valuable in investigating the anatomical and func-
tional benefits of inhibiting EGFR post-SCI. To test whether
PD168393 could suppress reactive astrogliosis and improve
the microenvironment for functional recovery following in-
jury, we used in vitro astrocyte scratch injury and in vivo
weight-drop SCI models to address this issue. Our results
show that PD168393 markedly facilitates a more favorable
environment for functional recovery after SCI by the ameli-
oration of excessive astrogliosis, which is promising as an
effective therapeutic intervention which could be applied in
t h ef u t u r et oC N St r a u m ai n j u r y .
Materials and methods
Spinal cord astrocyte culture
Spinal cord astrocytes from neonatal rat spinal cord were
prepared according to previously described methods [12].
Briefly, the spinal cords of one- to two-day-old old rat pups
were isolated following painless sacrifice. Meninges were
removed and the spinal cord was minced, passed through a
70 mm nylon mesh and then digested in 0.25% collagenase
(Sigma, St. Louis, MO, USA) in PBS, pH 7.4, for 10 to
20 minutes at 37°C. Cells were pelleted by centrifugation at
1,000 rpm for two minutes at 5°C and the final pellet was
suspended and cells were plated in culture flasks at a dens-
ity of 1× 106 to 3× 106 mL
-1 and maintained at 37°C in
95% O2/5% CO2 in DMEM supplemented with 10% FBS
(Hyclone) and 0.5 mg/mL penicillin/streptomycin. The
medium was changed 48 hours later and every two days
thereafter. During week 2 in vitro, non-astroglial cells were
removed by shaking [13]. The astrocytes remaining in cul-
ture were identified by immunostaining with anti-GFAP.
Approximately 95% of the cells were immunopositive for
GFAP. All experiments were performed on spinal cord as-
trocytes maintained for two to three weeks in culture.
In vitro scratch wound model and EGFR inhibitor treatment
A scratch wound model was produced as previously de-
scribed [14]. Lines were scratched in confluent monolayer
astrocytes with sterile plastic pipette tips and then the
detached cells and debris were rinsed out with fresh
medium PD168393 dissolved in dimethylsulfoxide (DMSO)
was added to the cultures after scratch injury at various con-
centrations (10 μM, 20 μM and 40 μM) (PD168393 group).
The final DMSO concentration in the culture medium was
0.2%. A control group of cells and an injured cell group
were treated with 0.2% DMSO and not PD168393 in the
culture medium. The remaining cell-free area were ob-
served under an Olympus phase contrast microscope
(Olympus, Tokyo, Japan) connected to a computer screen
and then analyzed with Image-Pro Plus analysis software
(Media Cybernetics, Inc., Silver Spring, MD, USA). Cells
were harvested at various time intervals (6, 12, 24, 48
and 72 hours) after injury.
Immunocytochemical staining of cultured astrocytes
The three cell groups were processed for anti-
phosphorylated EGFR (pEGFR), GFAP and DAPI (4,6-
diamidino-2-phenylindole) immunocytochemical staining
at 24 hours post-injury. The cells were fixed in 100%
methanol for ten minutes at room temperature and the
membranes of fixed cells were permeabilized with Triton
X-100. Nonspecific antibody binding was blocked by
incubation with 5% BSA in PBS at room temperature
for one hour. The cells were then simultaneously incu-
bated with both monoclonal mouse anti-pEGFR (1:100;
Abcam, Cambridge, UK) and polyclonal rabbit anti-GFAP
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3 × 10 minute PBS washes, the cells were incubated in a
m i x t u r eo ft w os e c o n d a r ya n t i b o d i e s :F I T C - c o n j u g a t e d
goat anti-rabbit immunoglobulin G (IgG) antibody (1:200;
Pierce, Wilmington, NC, USA) and cyanine 3 (Cy3)-
conjugated goat anti-mouse IgG antibody (1:200; Jackson
ImmunoResearch, West Grove, PA, USA) for one hour
at room temperature. DAPI staining was used to label
the nuclei.
In another set of experiments, sister-cultures of astro-
cyte monolayers were scratched and incubated with
600 ng/mL bromodeoxyuridine (BrdU) (Sigma, St. Louis,
MO, USA) to assess cell proliferation. After incubation,
the cells were processed for anti-BrdU, GFAP and DAPI
immunocytochemical staining at 6, 12, 24 and 48 hours
after injury according to a previous protocol [15]. Briefly,
after fixation and membrane permeabilization, nuclear
proteins were detached from the deoxyribonucleic acid
(DNA) by treatment with 2 M hydrogen chloride (HCl)
at 60°C for 30 minutes to allow antibody access to the
incorporated BrdU. The cells were washed in PBS and
blocked in 5% BSA for one hour. The mixture of two pri-
mary antibodies used was: monoclonal mouse anti-BrdU
(1:100; Sigma, St. Louis, MO, USA) and polyclonal rabbit
anti-GFAP (1:500; Sigma, St. Louis, MO, USA). Incubation
with the indicated primary antibodies was carried out
overnight at 4°C. After being washed in PBS, the cells
were incubated in a mixture of two secondary antibodies:
fluorescein isothiocyanate (FITC)-conjugated goat anti-
rabbit IgG antibody (1:200; Pierce, Wilmington, NC, USA)
and Cy3-conjugated goat anti-mouse IgG antibody (1:200;
Jackson ImmunoResearch, West Grove, PA, USA) for one
hour at room temperature. To determine the proportion
of BrdU-positive proliferating cells, the nuclei were labeled
with DAPI. Cells were counted next to the wound in five
random fields of vision. The results were viewed through a
fluorescence microscope (Olympus, BX51, Tokyo, Japan).
In control experiments, the primary antibodies were
omitted to confirm the specificity of the antibodies.
ELISA
The levels of TNF-α, induced nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2) and IL-1β in the conditioned
medium from normal cultured astrocytes (control group),
scratch wound astrocytes (injury group) and PD168393-
treated scratch wound astrocytes (PD168393 group)
were assayed by ELISA using Immunoassay Kits (R & D
Systems USA) that can detect concentrations as low as
10 pg/ml of the relevant protein, following the manufac-
turer’s instructions. Briefly, after constructing a standard
curve, several dilutions of the test sample were assayed
in duplicate for each protein using the appropriate kit.
Absorbance was read at 450 nm with a reference wave-
length of 570 nm by a VERSA max microplate reader
(Molecular Devices, Sunnyvale, CA, USA). Regression
analysis was then performed on standards and sample
concentrations were determined with reference to the
linear portion of the standard curve.
Animals and surgery
The animal procedures were performed in accordance
with protocols approved by the Institutional Animal Care
and Use Committee at Nanjing Medical University. Adult
female Sprague-Dawley rats (n=96; weight 220 to 250 g)
were randomly classified into SCI and sham-operated
groups. A T10 contusion injury was produced as previously
described [8,16]. Briefly, rats were anesthetized by intraperi-
toneal (ip) injection of ketamine (80 mg/kg) and xylazine
(10 mg/kg). Once rats were confirmed by toe-pinch to be
unconscious, a laminectomy was performed at thoracic
level T10. The spine was immobilized stereotaxically, and
weight-drop injury was induced using a standardized
instrument (New York University Impactor) releasing
aw e i g h t( 1 0g ,r o dd i a m e t e ro f2m m )f r o mah e i g h to f
12.5 mm on the exposed dura of the spinal cord, inflicting
a moderate contusion injury. Following SCI, rats were ran-
domly and blindly assigned to either PD168393 or vehicle
treatment groups. Immediately after injury, an osmotic
mini pump (Alzet Corp., Palo Alto, CA, USA) placed
between the shoulder blades was connected to a 32
gauge catheter and the catheter tip was positioned subdu-
rally on the dorsal side of the spinal cord over the center of
the injury through a small hole in the dura mater. In the
PD168393-treated group, the osmotic pump was filled
2 mM PD168393 (Sigma, St. Louis, MO, USA) dissolved in
5% DMSO (dissolved in 95% Hank’s balanced salt solution
(HBSS)), which was microinfused immediately after pump
placement at a rate of 0.5 μl/h for 14 days [7]. Control ani-
mals were only given vehicle solution (5% DMSO) lacking
PD168393. The overlying back muscles and skin were
then sutured. Following surgery, animals were placed
and recovered in a warm environment and were later
returned to their original housing facility. After 14 days,
the pumps were removed and then the wound was closed
with surgical suture. Sham-operated animals underwent
laminectomy alone. Bladders were expressed twice daily
until the animals resumed eating and drinking normally
and urinary incontinence disappeared.
Western blotting analysis
Rats in sham, injury, and PD168393-treated injury
groups were deeply anesthetized and sacrificed at day 14
post-injury (n =3 in each group for each time point). A
15 mm length of the spinal cord containing the injury
epicenter was quickly removed for animal tissue protein
analysis. For cell culture experiments, cultured astrocytes
were harvested at 24 hours after scratch injury. Protein ex-
tracts were prepared and Western blotting was performed
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equal amount of total protein were loaded on SDS-PAGE
(10% for EGFR/pEGFR; 12% for other components). After
transferring to membrane (300 mA, four hours for EGFR/
pEGFR; 250 mA, two hours for others), non-specific bind-
ing was blocked by a buffer containing 0.1% Tween 20, 2%
BSA, and 5% nonfat dry milk in TBS. Following blocking,
the membranes were incubated with primary antibodies
diluted in blocking buffer overnight at 4°C. Primary anti-
bodies used for Western blot were monoclonal mouse
anti-GFAP (1:1,000; Neomarkers, Fremont, CA, USA) for
reactive astrocytes, polyclonal rabbit anti-pEGFR (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal
rabbit anti-EGFR (1:500; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), polyclonal rabbit anti-CS-56 (1:500; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) to detect CSPGs
and rabbit anti-β-actin (1:2,000; Neomarkers, Fremont, CA,
USA) as a loading control. After washing the membranes
with 0.1% Tween 20 in TBS, the blots were incubated with
horseradish peroxidase-conjugated anti-mouse or anti-rabbit
IgG (1:2,000; Neomarkers, Fremont, CA, USA) at room
temperature for one hour and visualized with an enhanced
chemiluminescence (ECL) system (Thermo Fisher Scientific
Inc., USA). The membranes were scanned at 600 dpi, and
the digital images were quantitatively analyzed by a Kodak
Digital Science 1D system. Optical density (OD) of the sig-
nals was semiquantified and expressed as the ratio of OD
of the tested proteins to that of β-actin.
Immunocytochemistry staining of rat spinal cord sections
Rats in all groups were sacrificed at day 14 post-surgery for
EGFR, pEGFR, and GFAP double staining (n=5 in each
group), and at day 28 for GFAP, CSPGs and staining (n=5
in each group), and the tissue was dissected and processed
as previously described [8,17]. Briefly, the animals were
transcardially perfused with saline, followed by ice-cold 4%
paraformaldehyde. The spinal cord was harvested, and a
15-mm length, centered on the injury site, was analyzed.
The spinal cord was embedded in Tissue Tek OCTcom-
pound (Sakura) and rapidly frozen in nitrogen-cooled
isopentane, and stored at −80°C freezer until processing.
The tissue blocks were cut at 10 μm thickness, and sec-
tions were mounted on poly-L-lysine-coated glass slides
and stored at −20°C until further analysis.
Sections were washed in PBS and blocked in 5% normal
goat serum for one hour. For immunofluorescence double
labeling, sections were treated respectively with a com-
bination of two primary antibodies: mouse anti-GFAP
(1:300; Sigma, St. Louis, MO, USA) and rabbit anti-
EGFR (1:200; Sigma, St. Louis, MO, USA), mouse anti-
G F A P( 1 : 3 0 0 ;S i g m a ,S t .L o u i s ,M O ,U S A )a n dr a b b i t
anti-pEGFR (1:200; Sigma, St. Louis, MO, USA), rabbit
anti-GFAP (1:300; Sigma, St. Louis, MO, USA) and
mouse anti-CSPGs (1:200; Sigma, St. Louis, MO, USA)
overnight at 4°C. After 3 × 10 minute PBS washes, sec-
tions were incubated in a mixture of two secondary
antibodies: Cy3-conjugated goat anti-rabbit IgG anti-
body (1:300; Jackson ImmunoResearch, West Grove, PA,
USA) and FITC-conjugated goat anti-mouse IgG antibody
(1:300; Jackson ImmunoResearch, West Grove, PA, USA)
for one hour at room temperature. Finally, the slides were
washed twice in PBS and once in water for five minutes
each before being dried and cover-slipped with antifade
mounting media. Sections were observed under an
Olympus BX-51 light microscope (Olympus, Tokyo,
Japan) connected to a computer screen and then ana-
lyzed with Image-Pro Plus analysis software (Media Cy-
bernetics, Inc., Silver Spring, MD, USA).
Luxol Fast Blue staining and cresyl violet eosin staining
Four weeks post-injury, rats were sacrificed, and the
tissue was dissected and processed as stated previously.
For myelin quantification, Luxol Fast Blue (LFB) staining
(Sigma, St. Louis, MO, USA) was performed on 20 μm
thick cross-sections (n=5 in each group). Cryostat sec-
tions were processed according to the cryo-nerve Fast
Blue staining kit protocol (GenMed Scientifics Inc. USA).
The experimental protocol was described in detail in our
previous studies [8,20].
For quantitative analysis of the total lesion volume in
whole spinal cords and neuronal survival following injury
in all groups, cresyl violet eosin staining was performed
on 20 μm thick cross-sections (n=5 in each group) at the
fourth week after SCI. The experimental protocol was per-
formed as previously described [21,22].
Serial sections were used for data presentation. Sections
were visualized using an Olympus BX-51 light microscope
(Olympus, Tokyo, Japan). An unbiased estimation of the
percentage of lesion cavity (or volume of demyelination
region) was calculated using previously described methods
[22,23]. The percentage total volume of the injured tissue
was calculated by dividing the total lesion volume by the
total spinal cord volume [22,23]. For rescued motor
neuron counting, sections at 1 mm increments rostral and
caudal to the epicenter were selected and stained with cre-
syl violet and eosin. Motor neurons located in the ventral
horn (VH) with clearly visible nuclei on both sides of the
spinal cord were counted [22].
Behavioral outcome assessment
Open-field locomotor testing was performed by two
trained investigators using the 21-point Basso, Bresnahan,
and Beattie (BBB) locomotor scale [24] weekly post-injury.
Hindlimb locomotion was then scored from 0 to 21 points
(flaccid paralysis to normal gait). Five rats per each ex-
perimental group were used for behavioral analysis. All
open-field locomotor testing was performed by two
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scheduled testing date.
Residual urine
After SCI, the urinary function of all rats was disrupted and
the bladders were manually expressed twice daily. Urine
was collected during bladder expression and volumes were
recorded until sufficient (autonomic) bladder function had
recovered for at least three weeks [7].
Statistical analysis
Data are presented as mean ±standard deviation (SD).
Statistically significant differences between data (defined
as P<0.05) were evaluated by Student’s t-test or one-way
analysis of variance (ANOVA) followed by Tukey’s post
hoc test. For comparison between groups over time, a
multiple-measurement ANOVA was used.
Results
PD168393 inhibited EGFR phosphorylation in reactive
astrocytes following a scratch wound
To investigate whether EGFR phosphorylation increased
in scratch-induced reactive astrogliosis in vitro,t h es c r a t c h
model was used to determine the effects of injury on
astrocyte EGFR phosphorylation. Triple-labeling immuno-
fluorescent for pEGFR, GFAP and DAPI was performed at
24 hours post-injury. The normal cultured astrocytes
(control group) barely exhibited EGFR phosphorylation
(Figure 1A1-A4). In the injured group, however, most
astrocytes showed increased pEGFR immunoreactivity
at the ‘wound-edge’ (Figure 1B1-B4), which indicated
that a scratch wound could promote astrocyte EGFR
phosphorylation. More importantly, EGFR tyrosine kinase
specific inhibitor PD168393 administration significantly
inhibited pEGFR immunoreactivity in injured astrocytes
(Figure 1C1-C4), which provide further evidence that
PD168393 could inhibit EGFR phosphorylation in re-
active astrocytes. Western blot analysis also supported
PD168393 inhibition of EGFR phosphorylation and
GFAP expression in reactive astrocytes following injury
(Figure 1D-E).
PD168393 inhibited scratch-induced reactive astrogliosis
in vitro
To examine the effect of PD168393 on scratch-induced
reactive astrogliosis, our scratch wound model was used
and the dynamic changes in the morphology, mobility, and
proliferation of astrocytes responses to mechanical injury
were investigated. Six hours after injury, there were no ob-
vious changes in astrocyte morphology in either the injury
or PD168393 group, and cell debris was observed on the
surface of cells at the scratch margin (Figure 2A2-B2).
Twelve hours post-injury, the astrocytes extended tactile
hypertrophic processes towards the denuded area in the
injury group (Figure 2A3). However, the hypertrophic
changes in the processes of astrocytes in the PD168393
treatment group were less obvious (Figure 2B3). Twenty-
four hours after injury, multiple astrocytes with hyper-
trophic processes as well as many phase-bright spherical
somata appeared within the ‘wound-gap’ in the injury
group (Figure 2A4), which indicated that activated astro-
cytes and dividing cells migrated into the denuded area.
Interestingly, the cell density of the PD168393 treatment
group in the scratch area was smaller than the injury
group (Figure 2B4). Forty-eight hours after injury, a near
confluent monolayer of activated astrocytes was observed
within the wound-gap in the injury group (Figure 2A5).
Conversely, few astrocytes were observed in the wound-
gap in the PD168393 treatment group (Figure 2B5). In the
injury group, seventy-two hours after injury, activated as-
trocytes with hypertrophic processes gathered into a glial
scar-like formation at the wound-gap so that the scratch
wound was almost not visible (Figure 2A6). The scratch
wound was still distinct, however, in the PD168393 treat-
ment group at this time point as few activated astrocytes
were observed at the wound-gap (Figure 2B6). Quantifica-
tion revealed a reduction in the remaining cell-free area oc-
curred more rapidly in the injury group than the PD168393
group, indicating PD168393 inhibited proliferation of
activated astrocytes after injury.
In order to verify the inhibitory effect of PD168393 on
astroglial proliferation following in vitro injury, we per-
formed double-immunofluorescent labeling for GFAP
and BrdU at each designated time point post-injury
(Figure 2D-G). BrdU+ cell numbers in the wound area
were evaluated to determine scratch injury-induced
astrocyte proliferation. BrdU is generally considered a
marker of dividing cells [25] and is involved in both DNA
replication and repair. The number of BrdU +cells signifi-
cantly increased at 12 hours after injury, and peaked at 24
and 48 hours when the cell density approached confluence
in the wound site of injured group (Figure 2D1-D4, F).
PD168393 treatment decreased the percentage of
BrdU+cells compared to untreated scratch injury cul-
tures. The percentage of BrdU+cells (7.73% ±2.23%)
at the boundary area of the wound at 24 hours was 2.11-
fold lower than in untreated cultures (16.31%±3.26%). In
contrast to the injured group, PD168393 treatment also
decreased cell proliferation in areas adjacent to the scratch
injury at 48 hours (20.22%±3.31% versus 10.03%±3.23%)
(Figure 2E1-E4, G). These results indicate that PD168393
inhibited proliferation of activated astrocytes following
injury in vitro.
Astroglial cell proinflammatory cytokine secretion was
reduced by PD168393 following scratch injury in vitro
The concentration of TNF-α, iNOS, COX-2 and IL-1β
protein were assayed by ELISA at 12, 24 and 48 hours
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proinflammatory cytokine secretion of astroglial cells after
injury. As shown in Figure 3, 40 μM PD168393 significantly
decreased the levels of TNF-α,i N O S ,C O X - 2a n dI L - 1 β at
three different time points after injury (Figure 3A-D).
Twenty micromolar PD168393 treatment also reduced the
expression of TNF-α and iNOS at 48 hours after injury
(Figure 3A, B). Expression of COX-2 was also inhibited
by 20 μM concentration PD168393 treatment at 24 hours
after injury (Figure 3C). In addition, IL-1β protein
expression was inhibited by 20 μM PD168393 at three dif-
ferent time points post-injury (Figure 3D).
PD168393 inhibited EGFR phosphorylation in reactive
astrocytes following SCI
To determine whether PD168393 could inhibit EGFR
phosphorylation in reactive astrocytes following SCI,
we performed immunofluorescence double-labeling for
pEGFR and GFAP at two weeks following SCI. No EGFR
phosphorylation was observed in quiescent astrocytes as
Figure 1 PD168393 inhibited EGFR phosphorylation of astrocytes in an in vitro scratch wound model. Cultured astrocytes were
immunostained for pEGFR, GFAP and DAPI in control (A1-A4), injury, (B1-B4) and PD168393 (40 μM) treatment groups (C1-C4) at 24 hours after
injury (n =5 in each group). (A1-C1) immunolabeling for pEFGR, (A2-C2), GFAP, (A3-C3) DAPI and (A4-C4) for co-localization of pEGFR, GFAP
and DAPI. Scale bars=100 μm. Representative Western blots of pEGFR and GFAP expression are shown (n=3/group) (D). Semiquantitative analysis of
pEGFR as a ratio of EGFR loading and semiquantitative measurements of GFAP were obtained by normalization to β-actin (E).* P<0. 05 .
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served in the intact spinal cord (Figure 4A3). A large
number of pEGFR and GFAP double-immunofluorescent
positive cells surrounded the lesion center in the in-
jured spinal cord (Figure 4B3 and D3), which suggested that
EGFR phosphorylation was a common phenomenon in re-
active astrocytes post-SCI. Meanwhile, PD168393 adminis-
tration significantly inhibited pEGFR immunoreactivity in
astrocytes (Figure 4C3 and E3). As shown in Figure 4F-G,
Western blot results also supported that PD168393 inhibited
EGFR phosphorylation in reactive astrocytes following SCI.
PD168393 attenuated SCI-induced reactive astrogliosis
and production of CSPGs
The glial scar consists primarily of reactive astrocytes and
heterogeneous extracellular matrix proteins such as CSPGs.
To explore the effect of PD168393 on reactive astroglio-
sis following SCI, immunofluorescence double-labeling
for GFAP and CSPG was performed in sham, injury, and
PD168393-treated group at day 28 post-injury. As shown
in Figure 5B3 and D3, strong and extensive CSPG and
GFAP immunoreactivity was detected around the le-
sion, indicating glial scar formation. More importantly,
(See figure on previous page.)
Figure 2 PD168393 treatment slowed down scratch injury-induced reactive astrogliosis. Astrocytes were scratched and incubated in the
absence or with treatment of 40 μM PD168393. (A1-B1), (A2-B2), (A3-B3), (A4-B4), (A5-B5) and (A6-B6) are paired images taken from control 0,
6, 12, 24, 48 and 72 hour groups after scratch injury, respectively. Scale bars=100 μmi nB6 (applies to A1-B6). Graphical representation of
remaining cell-free area quantification over 72 hours after scratch injury (C). Data are expressed as fold change compared to control group
(0 hours). Values are expressed means± SD (n =5). Significant difference between time points was observed (*P< 0.05, #P< 0.01). Immunostaining
for Brdu, glial fibrillary acid protein (GFAP) and 4,6-diamidino-2-phenylindole (DAPI) at 6, 12, 24 and 48 hours after scratch injury in the injury
group (D1-D4) and PD168393 (40 μM) treatment group (E1-E4), respectively. Astrocytes were identified by GFAP immunostaining (green) and
nuclei were identified by DAPI labeling (blue). Astrocytes in S phase were identified by BrdU labeling (red). Insets in panels (D4) of co-localization
of phosphorylated epidermal growth factor receptor (pEGFR), GFAP and DAPI are shown at high magnification in (F). Scale bars= 100 μmi nE4
(applies to D1-E4); scale bars=20 μmi n(F). Percentage of astroglial cells with BrdU labeling at different times after scratch injury (G).* P< 0.05.
Figure 3 PD168393 inhibited proinflammatory cytokine/mediators secretion of astrocytes in a scratch wound model. TNF-α (A),i N O S(B),
COX-2 (C) and IL-1β (D) in conditioned medium from control, injury and PD168393 groups (at 10 μM, 20 μM and 40 μM concentration) were assayed
by ELISA at various time intervals (12, 24 and 48 hours after injury). *P<0.05, #P<0. 0 1.
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tivation but also inhibited CSPG upregulation at four weeks
after SCI (Figure 5C3 and E3). Western blot analysis also
revealed similar results (Figure 5F, G).
PD168393 alleviated demyelination and promoted the
survival of VH motor neurons following SCI
Pathology in tissue cross-sections was identified by the
following characteristics: areas of normal myelin ap-
peared bright blue, and demyelinated tissue appeared
blanched. There was a large unstained area at the le-
sion epicenter of the spinal cord in the vehicle-treated
group, suggesting weight-drop injury resulted in loss of
myelin. However, the PD168393-treated group had a
significantly reduced blanched demyelinated area at
the lesion epicenter of the injured spinal cord (Figure 6A).
Quantification of demyelination region volume showed that
PD168393 treated animals had a significant reduction in
demyelination region volume (Figure 6B), indicating
that PD168393 treatment effectively protected against
demyelination following traumatic contusive SCI.
Cresyl violet eosin staining photomicrographs showed
that there was no different between injury group and
PD168393 group in lesion cavity volume, although the
demyelinated region volume in the PD168393 group was
significantly smaller than the injury group. Also, increased
glial scarring around the lesion cavity was observed in the
injury group over the PD168393 group. VH motor neurons
at the epicenter and in 1 mm increments rostral and caudal
to the epicenter (1 to 4 mm) were counted at the fourth
week following SCI to determine whether PD168393 treat-
ment promoted neuronal survival following injury. Repre-
sentative cresyl violet eosin staining photomicrographs
showed the motor neurons in the VH (Figure 7B). As
quantified in Figure 7C, more residual motor neurons
were found in the VH at 3 and 4 mm rostral and caudal to
the lesion epicenter in the PD168393 group than in the in-
jury group, which indicated that PD168393 treatment pro-
moted the survival of VH motor neurons following SCI.
Locomotion and bladder function recovery was improved
by PD168393 post-SCI
To assess whether PD168393 could improve functional
outcome following SCI, motor function of rats were
assessed using a modified BBB hindlimb locomotor
rating scale over eight weeks after injury. One day after
SCI, all rats exhibited complete bilateral hindlimb paralysis,
no significant difference in the extent of locomotor dys-
function between the PD168393 and injured control group
was observed. By the first week following SCI, the injury
control animals had only hindlimb hip and knee movement
corresponding to a BBB score of 3. However, the
PD168393-treated animals had extensive movement of
three joints of the hindlimb (hip, knee and ankle), corre-
s p o n d i n gt oaB B Bs c o r eo f6 .R e c o v e r yi ni n j u r e dc o n t r o l
animals plateaued after four weeks with occasional weight
supported plantar stepping, and a mean BBB score of 10. In
contrast, the PD168393-treated animals continued to im-
prove until week 7 post-injury and showed consistent
weight supported plantar stepping with forelimb-hindlimb
coordination and an average BBB score of 14 (Figure 8A).
We also recorded residual urine volume of rats every
day for three weeks following injury. In vehicle-treated
rats, residual urine volumes peaked at seven days, slowly
decreased and continued to show significant yields at 21
days after injury; whereas residual urine volumes peaked
at four to six days, then rapidly decreased and we docu-
mented minimal residual urine volumes from 13 days after
injury in the PD168393-treated group. This indicated that
PD168393 treatment improved bladder recovery following
SCI (Figure 8B).
Discussion
In the present study, we investigated the effect of specific
EGFR inhibitor PD168393 on reactive astrogliosis and
proinflammatory cytokine secretion of reactive astrocytes
in a scratch injury in vitro model and on glial scar forma-
tion and microenvironment for axonal regeneration and
recovery in a spinal cord contusion rat model. Our results
showed that administration of PD168393 markedly inhib-
ited scratch-induced reactive astrogliosis and secretion of
proinflammatory cytokines/mediators by reactive astrocytes
in culture, as well as suppressing glial scar formation,
attenuating myelin loss, promoting the survival of VH
motor neurons and more importantly, ameliorating hind
limb motor functional and bladder recovery in SCI rats.
The EGF receptors regulate a wide range of cellular
processes including proliferation, differentiation, motility,
survival, angiogenesis and invasion [8,26]. Our study dem-
onstrated that the up-regulated phosphorylation of EGFR
(See figure on previous page.)
Figure 4 PD168393 inhibited epidermal growth factor receptor (EGFR) phosphorylation of astrocytes after spinal cord injury (SCI) in rats.
Spinal cord sections were immunostained for phosphorylated EGFR (pEGFR) and glial fibrillary acid protein (GFAP) at two weeks after SCI (n=5/group).
(A1-C1) GFAP, (A2-C2) pEFGR, and (A3-C3) co-localization of pEGFR and GFAP. Insets in panels (B1-C3) are shown at high magnification in panels
(D1-E3), respectively. Scale bars=500 μmi n(C3) (applies to A1-C3); scale bars=50 μmi n(E3) (applies to D1-E3). Representative Western
blots of pEGFR and EGFR expression (n=3/group), and β-actin was a loading control (F). Semi-quantitative measurements were obtained by
normalizing to β-actin (G).* P <0.05.
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http://www.jneuroinflammation.com/content/11/1/71occurred in astrocytes in vitro and in vivo following injury,
and is involved in the pathophysiology of SCI as suggested
by previous research [7,8]. Furthermore, EGFR ligands
stimulate astrocytes to secrete axon growth inhibitory
CSPGs and further contribute to formation of the glial scar
[6,27]. Interestingly, our results indicate that administration
of EGFR inhibitor PD168393 not only significantly inhibited
pEGFR immunoreactivity in astrocytes but also sup-
pressed GFAP expression after SCI. Together, these
findings strongly suggest that EGFR activation triggers
astrocyte reactivity following injury [6,8].
Reactive astrogliosis is one of the key cellular responses
to CNS injury and is considered a major impediment
to axonal regeneration [15]. The glial scar is a significant
barrier to axonal regeneration, in part because the
astrocyte-deposited extracellular matrix (ECM) includes
an array of proteoglycans, most notably the CSPGs [28-34].
Many studies have established that CSPGs inhibit neurite
outgrowth in vitro and restrict axonal regeneration in vivo
[34-38]. Our data in the present study show that PD168393
administration inhibited EGFR phosphorylation and GFAP
expression as well as reduced CSPG expression and attenu-
ated glial scar formation after SCI.
Astrocytes are important in both physiological and
pathological processes following SCI and other CNS
diseases [39,40], and reactive astrocytes serve as a potential
source of inflammatory cytokines [41]. Activated astrocytes
can produce the proinflammatory cytokines IL-6, IL-1α
and β,T N F - α and interferon γ, and others [34,42,43].
Such properties support a detrimental effect of excessive
reactive astrogliosis following SCI. High levels of these
cytokines can directly induce neuronal apoptosis and in-
hibit neurogenesis [44]. Co-activation of proinflammatory
cytokines following SCI can also be detrimental to neu-
rons by altering synaptic proteins [45]. In addition, some
aspects of the local inflammatory response contribute to
spread of secondary injury to potentially viable tissue
and lead to delayed apoptotic and necrotic neuronal cell
death hours to days after injury [46,47]. Oligodendrocytes
are one of the most sensitive glial cells and undergo exten-
sive apoptotic death in response to inflammatory injury.
Oligodendrocyte attrition can lead to further demyelination
of spared axons and impair their conductive capacity,
markedly limiting the recovery of neural function fol-
lowing SCI [8,48]. Our present results indicated that the
EGFR inhibitor PD168393 inhibited proinflammatory
cytokine secretion from active astroglial cells following
injury in vitro and protected oligodendrocytes and neu-
rons from death induced by the robust proinflammatory
cytokine release following SCI in rats. Therefore, PD168393
m a yb eap r o m i s i n gt h e r a p e u t i c for attenuating inflamma-
tory damage following SCI.
Microenvironmental conditions are important for neur-
onal survival, neurogenesis and neuron repair [49,50], and
the subtle change to this environment by cytokine secretion
is involved in pathological processes after SCI [51]. The
present study suggested that PD168393 could improve the
microenvironment following SCI by suppressing reactive
(See figure on previous page.)
Figure 5 PD168393 attenuated chondroitin sulfate proteoglycan (CSPG) production from reactive astrocytes after spinal cord injury
(SCI). Double-immunofluorescent labeling for CSPGs and glial fibrillary acid protein (GFAP) at four weeks after SCI (n= 5/group). (A1-C1) GFAP,
(A2-C2) CSPG, and (A3-C3) co-localization of CSPG and GFAP. Insets in panels (B1-C3) are shown at high magnification in panels (D1-E3). Scale
bars= 500 μmi n(C3) (applies to A1-C3); scale bars=50 μmi n(E3) (applies to D1-E3). Representative Western blots of GFAP and CS-56
expression (n=3/group), and β-actin was a loading control (F). Semi-quantitative measurements were obtained by normalizing β-actin loading
(G).* P<0.05.
Figure 6 PD168393 reduced demyelination after spinal cord injury (SCI). A 15 mm length of spinal cord centered at the injury site was
harvested at day 28 post-injury and serially sectioned (n= 5/group). Representative transverse Luxol Fast Blue stained sections at the epicenter
and in 1 mm increments rostral and caudal to the epicenter. Epicenter sections are indicated by arrows. Scale bar=1 mm (A). Graphical
representation shows statistically significant reduction in lesion cavity volume following PD168393 treatment as well as considerable decrease in
myelin loss (B) (n=5, *P< 0.05 compared to control).
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CSPGs deposit. Ultimately, improved functional outcome
was achieved.
However, controversial views on the effects of EGFR
inhibitor in SCI have been raised. Erschamber et al.s h o w e d
that local blockade of EGFR within the injured area leads
not only to structural but also functional recovery following
rat contusive SCI [7]. Alternatively, Sharp et al. reached an
opposite result after repeating these key experiments [52].
The discrepancies between these two studies may be ex-
plained by different conditions in animal model proce-
dures, drug delivery manner and data processing methods
[53]. The present study showed that EGFR phosphoryl-
ation was increased mostly in reactive astrocytes both
in vitro and in vivo. Inhibiting EGFR phosphorylation by
PD168393 reduced reactive astrogliosis and CSPGs
accumulation and proinflammatory cytokine/protein se-
cretion. Thus, PD168393 ameliorating excessive astroglio-
sis after injury can mediate through blocking EGFR in
activated astrocytes. Meanwhile, another EGFR family
member ErbB2 receptor is also associated with astrocytic
proliferation [54-56]. Severe gliosis exhibits consistently
expressed ErbB2, although normal, quiescent astrocytes
and low-grade reactive astrogliosis processes are not
associated with significant ErbB2 expression [56]. Since
PD168393 also acts as an inhibitor of ErbB2 phosphoryl-
ation [10,57], it cannot be excluded that the impairment
of astrogliosis by EGFR inhibitor may be mediated
through blocking ErbB2 receptor signaling.
Several other studies have explored the potential
mechanism by which EGFR inhibitor can promote spinal
cord damage axon regeneration. Qu et al.s h o w e dt h a t
Figure 7 PD168393 promoted survival of ventral horn (VH) motor neurons after spinal cord injury (SCI). Representative transverse cresyl
violet eosin stained sections of four weeks post-SCI at the epicenter and in 1 mm increments rostral and caudal to the epicenter. Epicenter
sections are indicated by arrows. Scale bar= 1 mm (A). Representative photomicrographs from four weeks post-SCI showing cresyl violet eosin
stained VH neurons at 4 mm rostral to the injury epicenter. Scale bar=50 μm (B). Graphical representation showing no statistically significant
difference in lesion cavity volume following treatment (n =5) (C). Comparison of VH neurons among different groups at various distances from
the injury epicenter (0) as well as 1 to 4 mm rostral (r) and caudal (c) to it (D) (n=5, *P<0.05).
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neuroinflammation-associated secondary damage and
promoted neuroprotection in rats post-SCI [18]. Microglial
activation plays an initial role and is also necessary in main-
taining astrogliosis following SCI [58]. Our study provides
another perspective on the ability of EGFR blockade to sup-
press reactive gliosis in SCI. EGFR inhibition by PD168393
has been shown to manipulate glial progenitors to generate
neurons but not glia in a SCI model [8], which indicates
that EGFR inhibition can suppress the number of prolifer-
ative astrocytes post-injury. Douglas et al. observed that
EGFR inhibitors promote neurotrophin production in glial
cells, however the mechanism of this phenomenon is still
unknown [59]. These studies provide proof-positive evi-
dence that EGFR inhibition can improve outcomes from
experimental SCI; however, the mechanisms of the bene-
fits from EGFR inhibition are still debated.
Conclusions
In summary, the present study shows that intervention
with PD168393 markedly inhibited scratch-induced react-
ive astrogliosis and proinflammatory cytokines/mediator
secretion of reactive astrocytes in vitro. More importantly,
local administration of PD168393 to the injured rat spinal
cord suppressed glial scar formation, attenuated mye-
lin loss, and ameliorated hind limb motor function and
bladder recovery in SCI rats. Our results demonstrate that
attenuation of astrogliosis, reduction of CSPG expression,
suppression of proinflammatory cytokine production and
decreasing myelin loss may be potential key mecha-
nisms of EGFR inhibitor effect on improving outcome
after SCI. The robust effect of EGFR inhibitor on promot-
ing functional recovery in a rat SCI model could make such
compounds particularly attractive candidates for clinical
treatment of SCI.
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Figure 8 PD168393 improved functional outcome and bladder recovery after spinal cord injury (SCI). The Basso, Bresnahan, and Beattie
(BBB) scores of hindlimb locomotion were assessed at day 1 post-injury and weekly thereafter. Repeated-measures ANOVA revealed significant
difference between injury and PD168393-treated animals (P<0.01) (A). The PD168393-treated rats had less residual urine compared with non-
treated injured rats. Statistical analysis between animal groups showed significant differences (P<0.05) (B) (n= 5/group).
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